Latest Headlines

Latest Headlines

Hatteras rounds up $90M to lead a biotech rebound in NC

Life sciences investor Hatteras Venture Partners has seen some sweeping changes in its native North Carolina over the past year, as anchor tenant GlaxoSmithKline is shedding more than 1,000 local jobs and disrupting the local biotech ecosystem. But all that displaced talent has created a wealth of potential for new startups, Hatteras said, and the firm has put together $90 million for a new fund designed to back the next generation of promising companies.

Bloomberg: Bureaucracy deterring digital health VC in Europe

Digital health startups attracted $4 billion in venture capital in the U.S. last year, compared with about $110 million in Europe.

Mystery solved: Star biotech team rallies behind a $36M diabetes spinout from Salk

The mystery of Ron Evans' new biotech startup has been solved. Armed with $36 million in cash from A-list venture investors and backed by a pro team recruited from Rich Heyman's Aragon/Seragon starring cancer drug startups, the prominent Salk investigator and his old buddy Heyman are coming out of stealth mode today with a new company called Metacrine.

Illumina sends off first three companies from genomics startup incubator

Illumina graduated the first three companies from its genomics incubator, Illumina Accelerator, months after the sequencing giant roped in new funds to back startups selected for the program.

Atlas' Padlock scoops up some GlaxoSmithKline assets in autoimmunity

Padlock Therapeutics, an Atlas Venture-seeded biotech startup, grabbed the rights to some potential drugs developed by GlaxoSmithKline, widening its arsenal of assets as it chases a novel approach to autoimmune disease.

Hype or hope? GlaxoSmithKline bankrolls a tiny startup in search of an HIV cure

A struggling GlaxoSmithKline has set up an economy-sized research spinout with the University of North Carolina at Chapel Hill that's short on cash and long--very, very long--on its promise to hunt for a cure for HIV.

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

The cascade of venture cash into CRISPR-Cas9 startups is continuing with no end in sight, despite a patent brawl brewing over who owns the technology. Today it's CRISPR Therapeutics' turn at the venture well, drawing $64 million in new VC cash that will fund a company that's based in Basel with deep and growing roots in Cambridge, MA. The new funding brings its total haul to $89 million, with GlaxoSmithKline's SR One and Celgene leading the way.

Atlas Venture unveils a $280M pure play biotech startup fund

Atlas Venture is unveiling a new $280 million fund today that will double down on its bet on cutting-edge drugs. Atlas relied on two close industry giants--Amgen and Novartis--and a mix of old and new investors to help raise a fund that easily broke through its $250 million cap.

Biotech spared in U.K. rejig of VC trusts

The United Kingdom is to change the laws governing startup investment vehicles known as Venture Capital Trusts (VCTs) but has opted against some of the dramatic alterations previously mooted. VCTs will still face new restrictions on the companies to which they can provide private equity cash, though.

Startup raises $3.9M to market device-app combo to calm panic disorder

Palo Alto Health Sciences has raised $3.9 million out of a proposed $7.1 million financing, according to an SEC filing. The startup will use the cash to back its FDA-cleared, at-home system to treat panic disorders.